Dr. Lal PathLabs Ltd operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Dr. Lal PathLabs Ltd with three other
pharmaceutical manufacturers in Asia:
Thyrocare Technologies Ltd
sales of 4.03 billion Indian Rupees [US$56.37 million]
of which 91%
was Diagnostic Testing Services),
Malaysian Genomics Resource Centre Berhad
(27.73 million Malaysian Ringgits [US$6.63 million]
Medical & Biological Laboratories Company Limited
based in Japan
(8.18 billion Japanese Yen [US$75.69 million]
of which 99%
was Reagent business).
Dr. Lal PathLabs Ltd reported sales of 12.03 billion Indian Rupees (US$168.36 million)
March of 2019.
increase of 13.9%
versus 2018, when the company's sales were 10.57 billion Indian Rupees.
Sales at Dr. Lal PathLabs Ltd have increased during each of the previous five years
(and since 2014, sales have increased a total of 116%).